AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.

Revenue
+9.96%
EPS
+267.0%
Free cash flow
−50.9%
Total debt
+23.8%

Quarter to September 2026, against a year earlier

19.41 0.54 −2.71%
Market cap
$6.8B
P/E
36.9×
Fwd P/E
44.2×
Dividend yield
—
F-score
7/9
Altman Z
1.94
Beneish M
−2.68
Dividend safety
n/a

AMNEAL PHARMACEUTICALS, INC. (AMRX) Book value per share

Alert me on Book value per share

AMNEAL PHARMACEUTICALS, INC.'s book value per share at the end of fiscal 2025 was −0.2×, compared with −0.4× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 1.6×. Over the past ten years it has ranged from −5.1× (fiscal 2017) to 15.3× (fiscal 2015); the current reading is higher than 27% of that period. AMNEAL PHARMACEUTICALS, INC. ranks 39th of 84 Drug Manufacturers Specialty & Generic companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 −0.2× —
FY2024 −0.4× —
FY2023 0.1× (90.68%)
FY2022 1.2× (50.54%)
FY2021 2.5× 5.33%
FY2020 2.3× (10.88%)
FY2019 2.6× (62.73%)
FY2018 7.0× —
FY2017 −5.1× —
FY2016 8.8× (42.39%)

Quarterly newest first

Period Book value per share Change
Sep 2026 1.6× 1,428.89%
Jun 2026 0.1× —
Mar 2026 −0.1× —
Dec 2025 −0.2× —
43 more quarters

Against its own ten years

Low −5.1× High 15.3×
Ten-year median 2.3×
Current reading's percentile 27

Book value per share against peers

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on AMRX